- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
EL1SSAR Data Shed Light on Leveraging Atezolizumab Plus Nab-Paclitaxel in PD-L1+ TNBC
May 16th 2025, 10:09pm
EL1SSAR data reinforce the importance of PD-L1 assessment to select patients with TNBC with the best outcomes on atezolizumab.
Pretreatment ctDNA Status Is Associated With Distant Recurrent-Free Survival in Early Breast Cancer
May 16th 2025, 10:01pm
Baseline ctDNA concentration was shown to be the most significant predictor of distant recurrence-free survival in patients with early breast cancer.
Zanidatamab/Chemotherapy Yields Responses and Is Safe in HER2-Expressing Metastatic Breast Cancer
May 16th 2025, 9:45pm
Zanidatamab/chemotherapy showed early antitumor activity with a manageable safety profile in patients with HER2-expressing metastatic breast cancer.
Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer
May 16th 2025, 8:28pm
Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.
Neoadjuvant Letrozole/Entrectinib Shows Limited Activity in Invasive Lobular Breast Cancer
May 16th 2025, 6:40pm
Frontline endocrine therapy plus entrectinib failed to decrease RCB to 0/1 in patients with invasive lobular breast carcinoma.
Iza-Bren Shows Preliminary Efficacy, Safety in Heavily Pretreated HER2–/HER2-low Breast Cancer
May 16th 2025, 4:41pm
Iza-bren was safe and displayed early clinical activity in patients with heavily pretreated breast cancer across both HER2-low and HER2-negative subgroups.
Analysis of PADA-1 Trial Highlights Kinetics and Determinants of ESR1 Mutations in HR+/HER2– Metastatic Breast Cancer
May 16th 2025, 12:51pm
An analysis from PADA-1 showed the emergence of ESR1 mutations was uneven over time in hormone receptor–positive, HER2-negative metastatic breast cancer.
OncLive Polls Spotlight Phase 3 Breast Cancer Studies Generating Buzz Ahead of ASCO 2025
May 16th 2025, 12:00pm
Breast cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer
May 15th 2025, 9:09pm
Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.
Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC
May 15th 2025, 9:00pm
Emiltatug Ledadotin generated initial responses and was tolerable in heavily pretreated patients with advanced/metastatic TNBC.
Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer
May 15th 2025, 8:09pm
Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.
Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer
May 15th 2025, 6:14pm
Adjuvant pertuzumab with trastuzumab and chemotherapy extended OS vs placebo with trastuzumab and chemotherapy in HER2-positive early breast cancer.
T-DXd Improves All Outcomes in Post-Hoc Look of DESTINY-Breast06 in HR+, HER2-Low/-Ultralow Metastatic Breast Cancer
May 15th 2025, 4:39pm
Treatment with T-DXd improved outcomes vs chemotherapy in pretreated patients with HR-positive, HER2-low/-ultralow metastatic breast cancer.
Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL
May 15th 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how the 5-year follow-up data from the ZUMA-2 trial reveal sustained clinical benefit and durable responses for patients with relapsed/refractory mantle cell lymphoma (R/R MCL) treated with brexucabtagene autoleucel, potentially reshaping treatment paradigms by demonstrating long-term efficacy of CAR T-cell therapy in a historically challenging hematologic malignancy.
Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL
May 15th 2025, 12:00pm
Unpacking Key Data from ASH 2024
Panelists discuss how the combination of lisocabtagene maraleucel (liso-cel) and ibrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as presented in the phase 1/2 TRANSCEND CLL 004 study, may redefine treatment strategies by highlighting the potential benefits of combining chimeric antigen receptor (CAR) T-cell therapy with targeted agents and reshaping perspectives on sequential vs combination approaches in high-risk CLL.
Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting
May 15th 2025, 12:00pm
Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.
Imlunestrant Plus Abemaciclib Provides Consistent Benefit Across Key Subgroups of ER+ Advanced Breast Cancer
May 14th 2025, 11:36pm
Subgroup analyses from EMBER-3 continued to demonstrated benefits with imlunestrant plus abemaciclib in ER-positive advanced breast cancer.
Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting
May 14th 2025, 12:00pm
To prepare for the 2025 ASCO Annual Meeting, breast cancer experts share the abstracts and discussions they’re most excited to see at the meeting.
Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025
May 9th 2025, 8:38pm
Poll results highlighted key lung cancer abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study
May 8th 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how insights from the Liso-cel combined with ibrutinib (ibr) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and small lymphocytic lymphoma (SLL) are highlighted through the primary results of the open-label, phase 1/2 Transcend CLL 004 study.